ESMO 2024 - European Society of Medical Oncology Congress
Sep 13 - Sep 17, 2024 | BarcelonaSpain
LARVOL is not affiliated with European Society of Medical Oncology Congress and all trademarks, logos, and brand names are property of their respective owners
Showing 351 titles linked to Trials
610O - Preliminary results from a Phase 1, first-in-human study of DS-9606a, a Claudin 6 (CLDN6)-directed antibody–drug conjugate (ADC), in patients (pts) with tumor types known to express CLDN6
605O - YL201, a novel B7H3-targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors: Results from a first-in-human phase 1 study
606O - Initial results from a first-in-human study of the B7-H4–directed antibody-drug conjugate (ADC) AZD8205 (puxitatug samrotecan) in patients with advanced/metastatic solid tumors
607O - Interim Results of a Phase 1 Study of SGN-PDL1V (PF-08046054) in Patients with PDL1-Expressing Solid Tumors
719MO - A Phase 1/2 study of Rinatabart Sesutecan (Rina-S) in Patients with Advanced Ovarian or Endometrial Cancer
721MO - Phase I, Two-Part, Multicenter First-In-Human (FIH) Study of TORL-1-23, A Novel Claudin 6 (CLDN6) Targeting Antibody Drug Conjugate (ADC) In Patient With Advanced Solid Tumors.
754P - Initial results from a first-in-human study of AZD5335, a folate receptor α (FRα)-targeted antibody-drug conjugate, in patients (pts) with platinum-resistant recurrent ovarian cancer (PRROC)
612MO - Preliminary Results from a Phase 1 Study of CFT1946, a Novel BIDAC Degrader in Mutant BRAF V600 Solid Tumors
1739P - Linnovate: A phase 1/2 study of safety/efficacy using lurbinectedin combined with ipilimumab and nivolumab for advanced soft tissue sarcoma (NCT05876715): Interim analysis of phase 1 part
1790P - Phase 2 data of lurbinectedin (LUR) and irinotecan (IRI) in relapsed small cell lung cancer (SCLC) patients (pts) with chemotherapy-free interval (CTFI)>30 days (d)
1725MO - IMMUNOSARC II master trial (phase II of sunitinib and nivolumab): results from the clear cell sarcoma (CCS) cohort. a GEIS, ISG, and UCL study.
58P - Efficacy and safety of liposomal irinotecan (nal-IRI) plus fluorouracil (5-FU) and leucovorin (LV) versus 5-FU/LV alone for advanced biliary tract cancer (BTC) after progression on gemcitabine-based therapy: A pooled analysis of the NIFTY and NALIRICC trials.
1130P - Phase II trial on nivolumab plus radiotherapy in patients with metastatic mucosal melanoma: PORTER-M3 trial
1433P - A phase I/II study of FG-M108 plus capecitabine and oxaliplatin (CAPOX) as first-line (1L) treatment for patients with CLDN18.2+/HER2- advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.
1519P - Real-world evidence on long-term survivors of metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with liposomal irinotecan: NALLONG study.